Table 2.
Distribution of Office-based Framingham Risk Score Components Among 787 Testicular Cancer Survivors and Matched Controlsa by Cancer Treatment
| Characteristic | Testicular Cancer Survivors | Controls | |||
|---|---|---|---|---|---|
| Total, N = 787 | EP, n = 284 | BEP Cycles ≤ 3, n = 342 | BEP Cycles ≥ 4, n = 161 | N = 787 | |
| Median age, y | 37.3 | 38.4 | 36.8 | 36.3 | 37.0 |
| Range, y | 18.7–68.4 | 20–68.4 | 18.7–65.6 | 20–59.1 | 20.0–70.0 |
| Median BMI, kg/m2 | 27.4 | 26.9 | 28.0 | 27.3 | 27.6 |
| Range, kg/m2b | 18.0–66.0 | 18.1–48.6 | 18.1–60.2 | 18.0–66.0 | 17.0–66.2 |
| Median SBP, mm Hg | 126 | 123 | 127 | 126 | 119 |
| Range, mm Hgc | 96–190 | 98–168 | 96–190 | 99–171 | 89–196 |
| BP treatment, n (%) | |||||
| No | 701 (89.1) | 254 (89.4) | 300 (87.7) | 147 (91.3) | 704 (89.5) |
| Yes | 86 (10.9) | 30 (10.6) | 42 (12.3) | 14 (8.7) | 83 (10.5) |
| Current smoker, n (%)d | |||||
| No | 721 (91.6) | 270 (95.1) | 313 (91.5) | 138 (85.7) | 565 (71.8) |
| Yes | 66 (8.4) | 14 (4.9) | 29 (8.5) | 23 (14.3) | 222 (28.2) |
| Diabetes, n (%) | |||||
| No | 768 (97.6) | 276 (97.2) | 332 (97.1) | 160 (99.4) | 757 (96.2) |
| Yes | 19 (2.4) | 8 (2.8) | 10 (2.9) | 1 (0.6) | 30 (3.8) |
Abbreviations: BEP = bleomycin, etoposide, and cisplatin; BMI = body mass index; BP = blood pressure; EP = etoposide and cisplatin; SBP = systolic blood pressure.
Controls were derived from the National Health and Nutrition Examination Survey (NHANES) and matched 1:1 to Platinum Study patients by age, race, and education (refer to Methods).
All BMI values were confirmed as accurate.
The P-value (t test between mean of log-transformed SBP between all Platinum Study patients vs. NHANES controls) is significant (P < .001).
The P-value (χ2 between all Platinum Study patients vs. NHANES controls) is significant (P < .001).